Affiliation:
1. Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232 Villigen, Switzerland
2. Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
Abstract
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity. Similar to other tumor cells, CSCs need to carry critical mutations and epigenetic changes to acquire their aberrant phenotype. Confirmed in various hematologic and solid malignancies, the critical need to deepen our understanding of CSC biology, including identification of CSC biomarkers, and develop novel CSC-targeted therapies has been clearly recognized. Here, we review the L1 cell adhesion molecule (L1CAM) as a CSC-associated biomarker in ovarian cancer. Furthermore, we inform on the promising potential of anti-L1CAM radioimmunotherapy with 161Tb as a novel CSC-targeted therapeutic approach to overcome CSC radioresistance in comparison to 177Lu.
Funder
Swiss Cancer Research
Mahari-Stiftung, Switzerland
Reference175 articles.
1. Reid, F. (2023). World Ovarian Cancer Coalition Atlas 2023—Global Trends in Incidence, Mortality, and Survival, World Ovarian Cancer Coalition.
2. Molecular characteristics and clinical behaviour of epithelial ovarian cancers;Hollis;Cancer Lett.,2023
3. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020;Cabasag;Int. J. Cancer,2022
4. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications;Duska;Ann. Oncol.,2017
5. Cancer stem cell definitions and terminology: The devil is in the details;Valent;Nat. Rev. Cancer,2012